PT1073467E - Formulacoes de co-solvente que compreendem um composo de vitamina d. - Google Patents

Formulacoes de co-solvente que compreendem um composo de vitamina d.

Info

Publication number
PT1073467E
PT1073467E PT99914970T PT99914970T PT1073467E PT 1073467 E PT1073467 E PT 1073467E PT 99914970 T PT99914970 T PT 99914970T PT 99914970 T PT99914970 T PT 99914970T PT 1073467 E PT1073467 E PT 1073467E
Authority
PT
Portugal
Prior art keywords
vitamin
understand
composition
solvent formulations
formulations
Prior art date
Application number
PT99914970T
Other languages
English (en)
Portuguese (pt)
Inventor
Li Lukchiu
Edward A Pec
Daniel H Robinson
Dennis A Stephens
Jantzi Kathee
Thomas B May
John P Oberdier
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22008769&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1073467(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of PT1073467E publication Critical patent/PT1073467E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT99914970T 1998-04-08 1999-03-22 Formulacoes de co-solvente que compreendem um composo de vitamina d. PT1073467E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/057,143 US6136799A (en) 1998-04-08 1998-04-08 Cosolvent formulations

Publications (1)

Publication Number Publication Date
PT1073467E true PT1073467E (pt) 2004-12-31

Family

ID=22008769

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99914970T PT1073467E (pt) 1998-04-08 1999-03-22 Formulacoes de co-solvente que compreendem um composo de vitamina d.

Country Status (11)

Country Link
US (2) US6136799A (cg-RX-API-DMAC10.html)
EP (1) EP1073467B1 (cg-RX-API-DMAC10.html)
JP (4) JP4664499B2 (cg-RX-API-DMAC10.html)
AT (1) ATE275974T1 (cg-RX-API-DMAC10.html)
AU (1) AU758989B2 (cg-RX-API-DMAC10.html)
CA (1) CA2326198C (cg-RX-API-DMAC10.html)
DE (1) DE69920201T2 (cg-RX-API-DMAC10.html)
DK (1) DK1073467T3 (cg-RX-API-DMAC10.html)
ES (1) ES2229693T3 (cg-RX-API-DMAC10.html)
PT (1) PT1073467E (cg-RX-API-DMAC10.html)
WO (1) WO1999051271A2 (cg-RX-API-DMAC10.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586661B1 (en) 1997-06-12 2003-07-01 North Carolina State University Regulation of quinolate phosphoribosyl transferase expression by transformation with a tobacco quinolate phosphoribosyl transferase nucleic acid
US6136799A (en) * 1998-04-08 2000-10-24 Abbott Laboratories Cosolvent formulations
EP1368467B1 (en) * 2000-11-07 2007-04-25 North Carolina State University Putrescine-n-methyltransferase promoter
CN100391464C (zh) * 2001-12-03 2008-06-04 诺瓦西股份有限公司 含活性维生素d化合物的药物组合物
EP1476201B1 (en) 2002-02-19 2008-12-24 Resolution Chemicals Limited Solvent-based sterilisation of steroids
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20060189586A1 (en) * 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
US20050148557A1 (en) * 2003-07-29 2005-07-07 Jin Tian Use of Vitamin Ds to treat kidney disease
US20060009425A1 (en) * 2004-05-28 2006-01-12 Leticia Delgado-Herrera Oral formulations of paricalcitol
CN101223135A (zh) * 2005-07-18 2008-07-16 特瓦制药工业有限公司 帕立骨化醇的制备
US20070166187A1 (en) * 2006-01-18 2007-07-19 Song Jing F Stabilization of paricalcitol using chlorobutyl or chlorinated butyl stoppers
CA2651283A1 (en) * 2006-05-15 2007-11-22 Wisconsin Alumni Research Foundation Pulmonary delivery of 1.alpha.,25-dihydroxyvitamin d3 and co-administration of parathyroid hormone or calcitonin
US20100075933A1 (en) * 2008-07-28 2010-03-25 Sunita Vijay Shelke Injectable compositions of vitamin d compounds
US20110033529A1 (en) * 2009-08-06 2011-02-10 Durga Prasad Samantaray Oral pharmaceutical paricalcitol formulations
EP2545940A1 (de) * 2011-07-14 2013-01-16 hameln rds gmbh Parenterale Zusammensetzungen
MY172886A (en) 2012-06-29 2019-12-13 Wisconsin Alumni Res Found Use of 2-methylene-19-nor-(20s)-1?25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism
ES2698403T3 (es) * 2012-12-27 2019-02-04 Pharmathen Sa Composición farmacéutica inyectable estable de agonista de receptor de vitamina D y proceso para su preparación
US10369161B2 (en) 2014-12-30 2019-08-06 Wisconsin Alumni Research Foundation Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism
US9539264B2 (en) 2014-12-30 2017-01-10 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
CN106265492B (zh) * 2015-06-04 2020-12-11 成都国为生物医药有限公司 一种含有帕立骨化醇的药物组合物及其制备方法
WO2018044468A1 (en) 2016-08-30 2018-03-08 Wisconsin Alumni Research Foundation COMBINATION OF LOW DOSE 2-METHYLENE-19-NOR-(20S)-1α, 25-DIHYDROXYVITAMIN D3 AND CALCIMIMETICS TO TREAT SECONDARY HYPERPARATHYROIDISM

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4198391A (en) * 1973-07-20 1980-04-15 R. P. Scherer Ltd. Pharmaceutical compositions
US4212886A (en) * 1978-11-01 1980-07-15 Survival Technology, Inc. Stabilized benactyzine hydrochloride
US4308264A (en) * 1981-01-28 1981-12-29 Abbott Laboratories Stabilized, dilute aqueous preparation of 1α,25-dihydroxycholecalciferol for neonatal administration
DE3316510A1 (de) * 1983-05-06 1984-11-08 Bayer Ag Parenterale formulierung von nimodipin, ein verfahren zu ihrer herstellung sowie ihre verwendung bei der bekaempfung von erkrankungen
US4588528A (en) * 1984-05-31 1986-05-13 Wisconsin Alumni Research Foundation 1,24-dihydroxy-Δ22 -vitamin D3 and process for preparing same
DE3437232A1 (de) * 1984-10-10 1986-04-17 Mack Chem Pharm Stabilisierte injektionsloesungen von piroxicam
US4594340A (en) * 1984-11-29 1986-06-10 Hoffmann-La Roche Inc. 25,26-dehydro-1α,24R-dihydroxycholecalciferol and 25,26-dehydro-1α,24S-dihydroxycholecalciferol and the epimeric mixture
US4855294A (en) * 1988-09-06 1989-08-08 Theratech, Inc. Method for reducing skin irritation associated with drug/penetration enhancer compositions
US5098899A (en) * 1989-03-06 1992-03-24 Trustees Of Boston University Method for therapeutically treating psoriatic arthritis using vitamin D analogues and metabolites
DK191889D0 (da) * 1989-04-20 1989-04-20 Bukh Meditec Kosmetisk middel
AU649057B2 (en) * 1990-08-24 1994-05-12 Wisconsin Alumni Research Foundation Methods and compositions containing vitamin D compounds for improvement of skin conditions
US5502224A (en) * 1991-06-04 1996-03-26 Marigen, S.A. Biotenside esters and phosphatides with vitamin-D and vitamin-E compounds
FR2677884B1 (fr) * 1991-06-20 1993-07-09 Oreal Composition pour freiner la chute des cheveux a base de pyrimidines n-oxyde trisubstitues ou leurs derives sulfoconjugues, nouveaux composes pyrimidines n-oxyde ou leurs derives sulfoconjugues.
AU667675B2 (en) * 1991-06-28 1996-04-04 University Of Miami Method of preventing and treating chemotherapy-induced alopecia
GB9201920D0 (en) * 1992-01-29 1992-03-18 Leo Pharm Prod Ltd Novel treatment i
JPH05246891A (ja) * 1992-03-09 1993-09-24 Kobayashi Seiyaku Kogyo Kk 安定な抗膵炎用注射液
KR960013798B1 (ko) * 1992-04-24 1996-10-10 재단법인 한국전자통신연구소 평면 도파로형 공간 스위치
AU5861396A (en) * 1995-05-19 1996-11-29 Abbott Laboratories Stable aqueous formulations of 1alpha,25-dihydroxycholecalci ferol for parenteral administration
US5597815A (en) * 1995-07-13 1997-01-28 Wisconsin Alumni Research Foundation Prevention of hyperphosphatemia in kidney disorder patients
AU2588297A (en) * 1996-04-04 1997-10-29 Ortho Pharmaceutical Corporation Liposome-based topical vitamin d formulation
DE69804169T2 (de) * 1997-06-27 2002-08-29 Akzo Nobel N.V., Arnheim/Arnhem Oral anzuwendende flüssige Arzneilösung
CA2211949A1 (en) * 1997-07-21 1999-01-29 David Farley Johnson Nonaqueous compositions for parenteral administration
US6136799A (en) * 1998-04-08 2000-10-24 Abbott Laboratories Cosolvent formulations

Also Published As

Publication number Publication date
DE69920201T2 (de) 2005-09-29
JP2014129360A (ja) 2014-07-10
AU3359899A (en) 1999-10-25
DK1073467T3 (da) 2005-01-03
JP5887368B2 (ja) 2016-03-16
WO1999051271A2 (en) 1999-10-14
WO1999051271A3 (en) 1999-11-18
EP1073467A2 (en) 2001-02-07
CA2326198A1 (en) 1999-10-14
JP2016053046A (ja) 2016-04-14
EP1073467B1 (en) 2004-09-15
JP5548079B2 (ja) 2014-07-16
US6361758B1 (en) 2002-03-26
US6136799A (en) 2000-10-24
JP2011037860A (ja) 2011-02-24
AU758989B2 (en) 2003-04-03
ES2229693T3 (es) 2005-04-16
ATE275974T1 (de) 2004-10-15
JP2002510652A (ja) 2002-04-09
CA2326198C (en) 2009-06-09
JP4664499B2 (ja) 2011-04-06
DE69920201D1 (de) 2004-10-21

Similar Documents

Publication Publication Date Title
ATE275974T1 (de) Zusammensetzungen enthaltend glykolderivate, alkohole und vitamin d
BR9611802A (pt) Composições farmacêuticas
ES2110377T1 (es) Formulacion galenica de fenofibrato y aplicacion de la misma.
NO991152D0 (no) Stabil farmas°ytisk blanding inneholdende 4,5-epoksy-morfinan-derivat
BR9810495A (pt) Composição farmacêutica
DK0762896T3 (da) Tocopherol-sammensætninger til levering af biologisk aktive stoffer
BR0215184A (pt) composições farmacêuticas de derivados de taxano oralmente ativos tendo biodisponibilidade aumentada
DE69620877D1 (de) Arzneimittelformulierungen für il-12
DK1033981T3 (da) Formuleringer og fremgangsmåder til nedsættelse af antineoplastiske midlers toksicitet
PA8453201A1 (es) Formulaciones farmaceuticas que contienen voriconazol
ES2190075T3 (es) Formulaciones farmaceuticas solidas que contienen una mezcla fisica de sulfoalquil-eter-ciclodextrina y un agente terapeutico.
ES2175413T5 (es) Formulaciones de aerosol
TR199801861T2 (xx) Farmas�tik olarak yararl� bile�imler.
AR021370A1 (es) Composiciones farmaceuticas inyectables estabilizadas que contienen agentes anti-neoplasicos taxoides
DE60019334D1 (de) Antivirale arznei
AU3868997A (en) Pharmaceutical composition containing osteogenesis-promoting substance and a polyethylene glycol
BR9802537A (pt) Método para anestesiar um paciente humano antes de cirurgias de porte dose unitária e sistema farmacêutico para administração
HRP20010684B1 (hr) Izravno stlaciva matrica za kontrolirano otpustanje jednostruke dnevne doze klaritromicina
BR0113165A (pt) Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados
BRPI9916820B8 (pt) composição compreendendo 9[2[[bis[(pivaloilóxi)metil]fosfono]metóxi]etil]adenina, comprimido ou cápsula e método
TR200200683T2 (tr) Oral kontrollü salıverme formülasyonları.
ATE236885T1 (de) Hydrazono-benzazulen-derivate, pharmazeutische zusammensetzungen und zwischenprodukte
DK0981363T3 (da) Somatostatinagonister til reduktion af legemsvægt
ES2136965T3 (es) Derivados de 17-hidroxiiminoalquil y 17-hidroxiiminometilalquenil ciclopentanperhidrofenantreno activos sobre el sistema cardiovascular un procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
AR015375A1 (es) Derivados de estrenos, el uso de los mismos para la manufactura de un medicamento, y composicion farmaceutica que los comprende.